Go to content

Publications

510 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Advice - reimburse vutrisiran (Amvuttra®) for the treatment of one particular form of amyloidosis

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse vutrisiran ...

    Report | 29-08-2024

  2. Advice - reimburse olipudase alfa (Xenpozyme®) for the treatment of Niemann-Pick disease

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse olipudase alfa ...

    Report | 21-08-2024

  3. Advice - reimburse mirikizumab (Omvoh®) for the treatment of ulcerative colitis

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse mirikizumab (Omvoh®) ...

    Report | 07-08-2024

  4. Advice - re-extend the conditional inclusion procedure for ataluren (Translarna®)

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to re-extend the conditional ...

    Report | 06-08-2024

  5. Advice - reimburse omalizumab (Xolair®) for the treatment of severe asthma

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport to reimburse omalizumab (Xolair®) from ...

    Report | 05-08-2024

  6. Advice - reimburse empagliflozin (Jardiance®) for treating Von Gierke disease and Fanconi-Bickel syndrome

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to extend the reimbursement ...

    Report | 02-08-2024

  7. Advice - reimburse baricitinib (Olumiant®) for treatment of severe alopecia areata

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport to reimburse baricitinib (Olumiant®) ...

    Report | 31-07-2024

  8. Advice - reimburse cipaglucosidase alfa (Pombiliti®) in combination with miglustat (Opfolda®) for the treatment of Pompe disease

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport to reimburse cipaglucosidase alfa ...

    Report | 30-07-2024

  9. Advice - do not reimburse teclistamab (Tecvayli®) for the treatment of multiple myeloma

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to not reimburse teclistamab ...

    Report | 10-07-2024

  10. Advice - reimburse dostarlimab (Jemperli®) for the treatment of endometrial cancer

    The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to reimburse dostarlimab ...

    Report | 10-07-2024

Go to